Cendakimab
As of the edition of 20 October 2026, Cendakimab is an antibody: in active development; acts on IL13.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2014
- Kind
- Antibody
- Registered trials
- 11, 0 stopped early
- Disease areas
- Immune system; Digestive system; Blood and lymph; Inherited and neonatal; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL13 | Interleukin-13 | P35225 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AbbVie | Lead sponsor of trials | 2009 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2014 to now |